Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b

NCT00003715 is registered in ClinicalTrials.gov with AVAX Technologies as lead sponsor.

NCT NCT00003715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Lead sponsor
AVAX Technologies
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 1998
Completion date
Not reported
Enrollment
425 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)